Novel TLR 7/8 agonists for improving NK cell mediated antibody-dependent cellular cytotoxicity (ADCC)

Abstract There is a significant interest in designing therapeutic agents that can enhance ADCC and thereby improve clinical responses with approved antibodies. We recently reported the combination of an imidazoquinoline-based TLR7/8 agonist (522) with a monoclonal antibody improved ADCC in vitro and...

Description complète

Enregistré dans:
Détails bibliographiques
Auteurs principaux: Vidhi Khanna, Hyunjoon Kim, Wenqiu Zhang, Peter Larson, Manan Shah, Thomas S. Griffith, David Ferguson, Jayanth Panyam
Format: article
Langue:EN
Publié: Nature Portfolio 2021
Sujets:
R
Q
Accès en ligne:https://doaj.org/article/27dcaeb327f34221a5a50d887ce3dbbf
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires